The Pre-Treatment Workup: A Checklist Reader Can Bring

The pre-treatment workup is the half of the protocol the consumer press almost never writes about — and it is, on careful reading, the half that separates the clinics one returns to from the clinics one regrets. The reader who arrives at a Gangnam stem cell consultation holding a folder of recent labs, a current imaging study, and a clean list of medications does not, in any obvious sense, look more sophisticated than the reader who arrives empty-handed; the difference is felt later, in the consultation cadence, and again in the protocol that emerges. 做嘢之前要齊家伙, an aunt in Lee Garden Three used to say of her dressmaker — that one ought to bring one's own thread. The advice translates almost too neatly to the regenerative-medicine workup.

What the workup is, and why it precedes the protocol

A pre-treatment workup is, in its plainest definition, the set of clinical investigations a responsible clinic asks for before a stem cell session is scheduled — and the gap between what a clinic actually asks for and what a careful reader ought to bring is, in my reading, where most of the avoidable disappointment in this field accumulates. The workup serves three quiet purposes at once. It establishes baseline tissue and systemic health, so that any post-protocol change can be compared against something measurable. It identifies contraindications — active infection, undiagnosed malignancy, certain autoimmune flares, particular medication exposures — that would either defer or reframe the protocol on offer. And it provides the practitioner with the granular, indication-specific information that allows the protocol to be matched to the patient rather than ordered from a menu.

The better Gangnam clinics, in my reading, will request a workup before the consultation rather than after — the request itself reads as a signal that the protocol will be patient-led rather than schedule-led. A clinic that is comfortable booking a same-day session without recent imaging, recent bloodwork, or a full medication review deserves a slow second pass; the absence of a workup is, almost without exception, the absence of a protocol. What recommends a careful clinic is not the elaborateness of the request but the proportionality of it — the workup should match the indication, no more and no less.

How long the workup tends to remain valid

Most clinics treat bloodwork as current within three months and imaging as current within six to twelve months, depending on the indication. Patients report that the practitioners who take the field seriously will repeat any study that falls outside this window rather than work from older data — and that, in turn, is one of the more reliable signals of a careful clinic.

The bloodwork the careful reader should expect

The pre-treatment bloodwork panel, for most contemporary stem cell protocols, sits within a fairly stable range — and the cosmopolitan reader who has done a recent annual physical is often closer to ready than they realise. The complete blood count, the comprehensive metabolic panel, and a coagulation study form the spine of the workup; together they speak to bone marrow function, organ baseline, and bleeding risk respectively. Inflammatory markers — C-reactive protein, erythrocyte sedimentation rate — are typically added, since several stem cell protocols are deferred when systemic inflammation is acute. Infectious-disease serology is, in most regulated frameworks, mandatory rather than optional: hepatitis B and C, HIV, syphilis, and in many jurisdictions HTLV-1 are screened both for the patient's own protection and for the safety of the laboratory handling the cells.

Indication-specific additions follow a sensible logic. Aesthetic and hair protocols often add a hormone panel — thyroid function, ferritin, vitamin D, and in some cases androgen levels — since several of the conditions stem cells are asked to address have a systemic underlay the consultation should not flatten. Orthopaedic protocols may add an inflammatory autoimmune panel where clinically indicated. Tumour markers, in patients with risk factors, are sometimes requested as part of a wider screening rather than as a definitive instrument; the practitioner's care here is one to watch for. The U.S. National Institutes of Health Office of Dietary Supplements maintains a public reference set on common biomarkers that the careful reader may find useful as a frame of reference — it is, of course, a reference and not a substitute for the clinic's own panel.

• Complete blood count (CBC) — bone marrow and immune baseline
• Comprehensive metabolic panel — kidney, liver, electrolytes
• Coagulation study (PT/INR, aPTT) — bleeding risk
• Inflammatory markers (CRP, ESR) — systemic activity
• Infectious-disease serology — HBV, HCV, HIV, syphilis, HTLV-1 where required
• Indication-specific additions — hormones, autoimmune panel, tumour markers as clinically warranted

The imaging that the indication should drive

Imaging, in the pre-treatment workup, is where the indication's specificity reveals itself most plainly — and the patient who brings a recent, well-conducted study from a reputable institution often shortens the consultation by a meaningful margin. For orthopaedic protocols, magnetic resonance imaging remains, in most clinical settings, the modality of choice; the soft-tissue contrast it offers is the kind that the cells the clinic will discuss can plausibly be asked to address. A 1.5-Tesla or 3-Tesla MRI of the indicated joint, performed within the last six to twelve months and read by a musculoskeletal radiologist, is the better part of a knee, shoulder, or spine workup. Plain radiographs are still a useful adjunct — they read alignment and bone-on-bone change in ways MRI does not — and ultrasound has a quiet but expanding role in tendon and ligament work where dynamic assessment matters.

For aesthetic and dermatological indications, imaging is generally narrower in scope but no less considered. Some clinics use high-frequency ultrasound or VISIA-style imaging to document baseline skin quality before the protocol begins; these are useful primarily for comparison rather than for diagnosis, and the careful reader may ask whether the same protocol will be used at follow-up. For systemic and intravenous protocols, recent chest imaging — a chest X-ray within twelve months, in some frameworks a low-dose CT in patients with smoking history — is sometimes requested as part of a wider safety screen. The principle that recommends itself across all categories is one of proportionality: imaging should answer a question the protocol is going to act on, and not be ordered for its own sake. 做嘢要對症, as the Hong Kong saying has it — the work should fit the case.

What to bring on a disc, and what on a portal

Most Gangnam clinics will accept imaging on either a portable hard drive, a CD/DVD, or via a hospital portal — and the careful reader will, where possible, bring the original DICOM files rather than only the radiologist's report. The cells the clinic will discuss are matched to anatomy the practitioner can see, and the report alone, however well written, is one degree removed from the image itself.

The medication review the patient should compile

A medication review is, in regenerative-medicine practice, far more than a formality — and the patient who arrives with a single A4 sheet listing every prescription, supplement, and intermittent agent of the last twelve months has done the practitioner a real service. Several drug categories interact meaningfully with stem cell protocols. Anticoagulants and antiplatelet agents — warfarin, direct oral anticoagulants, aspirin at cardioprotective doses — affect bleeding risk for any procedure that involves a draw or a local injection; most clinics will discuss bridging or pausing strategies with the prescribing physician rather than unilaterally. Immunosuppressants and biologic agents — TNF-alpha inhibitors, JAK inhibitors, certain monoclonal antibodies — affect both the patient's resident repair machinery and the regulatory environment the introduced cells will encounter; the protocol may need to be deferred, modified, or escalated depending on the agent and the indication.

Supplements deserve more attention than they typically get. High-dose vitamin E, fish oil, ginkgo, and several traditional Chinese formulations have antiplatelet properties that the practitioner should know about; high-dose curcumin and certain adaptogens have immunomodulatory profiles that, while not always contraindicated, may interact with the signalling cascade the protocol relies on. Recent vaccinations, recent biologic infusions, recent steroid courses — both oral and intra-articular — are all worth noting on the same sheet. The practitioner who reads such a list slowly, asks unhurried questions, and updates their plan in plain language is, almost without exception, the practitioner one wants. The list itself, like the bloodwork and imaging that flank it, is less a document than a conversation starter.

• All current prescriptions — name, dose, indication, prescribing physician
• Anticoagulants and antiplatelet agents — including low-dose aspirin
• Immunosuppressants, biologics, and recent infusions
• Steroids — oral courses and intra-articular injections in the last 12 months
• Supplements and traditional formulations — vitamin E, fish oil, ginkgo, curcumin, herbal preparations
• Recent vaccinations and recent surgeries — both within the last six months

The history and lifestyle frame the consultation will draw on

A pre-treatment workup is incomplete without the narrative half — the history, lifestyle, and goal-setting frame that the consultation itself will draw on. The cosmopolitan reader who has lived across three time zones, eaten across four cuisines, and trained on several different continents tends to underestimate how much of this matters to a regenerative protocol. Sleep architecture, stress baseline, alcohol intake, smoking history (current and historical), exercise pattern, dietary frame — each of these inputs feeds into the resident tissue's capacity to respond to the signalling cascade the protocol will rely on. The practitioner is not asking these questions to moralise; they are asking because the cells the clinic will discuss work with the body the patient brings.

A careful reader should also walk in with a goal frame the practitioner can read — not a list of demands, but a calibrated sense of what improvement would look like and over what window. For an orthopaedic indication, this might be: a return to a 5km walk without next-day stiffness, by month three. For an aesthetic indication: a measurable improvement in skin quality at the four-month follow-up, photographed under the same protocol. The practitioner's response to such a frame is itself diagnostic of the clinic — the careful clinic will calibrate the goal in conversation, hedge appropriately, and decline to promise. The clinic that promises, rather than calibrates, is generally one to leave on the page. The honest conversation here, more than any single test on the panel, is what the workup ultimately enables.

The questions worth holding for the consultation

What is the cell source, the preparation, and the regulatory framework under which it is supplied. What is the published evidence for this indication at this dose. What is the protocol if the first session does not produce the calibrated effect. What is the aftercare line for the first week, and who answers it on a Sunday. The reader who walks in with these four questions tends to walk out with a clearer protocol — and, sometimes, a clearer reason to defer.

What the workup deferral or modification can look like

A workup that returns a finding which defers or modifies the protocol is, in my reading, one of the more underappreciated outcomes of the pre-treatment process — and the practitioner who treats such a finding as good news, rather than as a setback, is generally the practitioner one wants to keep. The most common deferrals one sees in the published literature are for active infection, recent surgery within the protocol's exclusion window, anticoagulant timing that requires bridging coordination, and inflammatory marker elevations that suggest a systemic process the protocol should wait on. Less commonly, the workup uncovers a clinically silent finding — a hormone abnormality, an unexpected imaging finding, a coagulation parameter outside reference range — that warrants its own investigation before the regenerative question is reopened.

Modifications are subtler. A patient with an unfavourable bloodwork profile may be offered a delayed protocol with a 6-week interim regimen; a patient on a biologic may be offered a session timed to the medication's trough; a patient with bilateral indication may be offered a sequential rather than simultaneous protocol. Each of these reads as the protocol being shaped to the patient rather than the reverse — and the careful reader should welcome each as a signal of competent practice. Studies suggest, with appropriate hedging, that protocol-modified outcomes in such cases are no worse, and sometimes meaningfully better, than rushed unmodified ones. The clinic that treats the workup as a checkpoint rather than a formality is, in my reading, the clinic that returns its patients to themselves more reliably.

• Active infection — typically defers protocol until resolved
• Recent surgery — typically defers within an indication-specific window
• Anticoagulant therapy — coordinated bridging with prescribing physician
• Elevated inflammatory markers — defer or investigate before scheduling
• Unexpected imaging finding — investigate before reopening regenerative question
• Pregnancy or lactation — generally exclude across most protocols

How the workup compares with adjacent regenerative protocols

The pre-treatment workup varies meaningfully across the broader regenerative landscape — and the cosmopolitan reader who is comparing protocols across modalities should hold the table below as a reference rather than as a ranking. Each modality is matched to a different physiological question, draws on a different preparation logic, and asks a slightly different workup of the patient. The categorical view, set out without comparative judgement, is the one the careful reader is best served by; one reads such a table the way one reads a tasting note, for what each option offers rather than for what is best.

The table is illustrative rather than prescriptive. A clinic that combines two modalities — for instance, an autologous PRP draw layered with a cell-conditioned topical after a fractional laser — may set out a workup that draws on more than one column. The reasoning, where the clinic is operating responsibly, will be set out in writing; the careful reader should ask for that reasoning before scheduling. The point is less that one workup is heavier than another and more that each is calibrated to the question the protocol is asking. Patients report, where the workup has been proportionate to the indication, a meaningfully different consultation experience — less like a standardised intake, more like a brief one walks into with their own folder.

Frequently asked questions

The questions below tend to arrive most often from cosmopolitan readers planning a Gangnam consultation around a wider travel itinerary — and the answers below are general, non-prescriptive, and intended for orientation rather than for guidance on any specific protocol.

“The workup is less a document than a conversation starter — and the practitioner who reads it slowly, asks unhurried questions, and updates the plan in plain language is, almost without exception, the practitioner one wants.”

An editorial reading of the pre-treatment frame

Frequently asked questions

How far in advance of travel should I complete the workup?

Most cosmopolitan readers find that a four-to-six-week lead time is comfortable — long enough for the clinic to receive the imaging and bloodwork, request any indication-specific additions, and offer a meaningful pre-arrival consultation. Patients report that doing the workup in the home jurisdiction, where the radiologist is known and the lab is familiar, tends to produce cleaner data than rushing the same panel in the first 48 hours after arrival.

Will the clinic accept results from my home country?

Generally yes, where the laboratory and imaging facility are reputable and the reports are in English or a supported language. Most Gangnam clinics that work with international patients are comfortable with U.S., U.K., Hong Kong, and Singapore institutional reports; some will request that infectious-disease serology be repeated locally if the home result is older than three months. The careful reader should confirm acceptance with the clinic in writing before booking flights.

Should I bring the original DICOM files or only the report?

Where possible, both. The radiologist's report is the practitioner's first read, but the DICOM files allow the clinic to review the imaging directly with their own musculoskeletal or aesthetic specialist. Patients report that the more careful clinics will decline to schedule without access to the imaging itself, and the convention is generally to bring the files on a portable drive or, in some cases, share via a secure portal.

What happens if the workup uncovers something unexpected?

The practitioner should walk the patient through the finding in plain language, contextualise it against the proposed protocol, and recommend either a deferral, a modification, or an investigation. Studies suggest that the clinics most comfortable with deferrals are also the clinics with the cleanest published outcome data — a correlation worth holding in view. The reader should regard a deferral as a sign of careful practice, not as a setback.

Do I need to fast for the bloodwork?

For most contemporary panels, an overnight fast of eight to twelve hours is preferred — particularly where lipid and metabolic markers are part of the panel. The infectious-disease serology and CBC do not require fasting, but it is generally simpler to do the full panel in a single morning visit. The clinic or referring laboratory will set out the exact instructions, and the careful reader should follow them rather than improvise.

Should I pause my supplements before the session?

Many clinics ask for a pause of seven to fourteen days on antiplatelet supplements — high-dose vitamin E, fish oil, ginkgo, certain herbal formulations — before any local injection or harvest protocol. Curcumin and high-dose adaptogens are generally discussed case by case. The pause should be agreed in writing with the practitioner, not improvised; abrupt cessation of certain agents can have its own implications worth discussing.

How does the workup differ for aesthetic versus orthopaedic indications?

Aesthetic protocols typically rest on a lighter panel — CBC, basic metabolic, infectious serology, hormone profile where relevant, photometric baseline imaging. Orthopaedic protocols add a fuller imaging study (MRI of the indicated joint, plain films, sometimes ultrasound) and often a more detailed inflammatory and autoimmune frame. The principle of proportionality holds: the workup should match the question the protocol is asking, no more and no less.

Is the workup itself covered by insurance?

In most jurisdictions, the diagnostic components of the workup — bloodwork, MRI, plain radiographs — are at least partly covered when ordered by a licensed physician, even where the regenerative protocol itself is not. The reader should consult with their insurer in advance and request the relevant referrals from a primary-care or specialist physician at home, where this approach is open. The clinic in Gangnam can provide a recommended panel list for the home physician to draw on.